SOURCES SOUGHT
B -- Breast Cancer Survivors Cohort � Late Effects of Breast Cancer Treatments
- Notice Date
- 1/15/2020 1:44:01 PM
- Notice Type
- Sources Sought
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- NIH NCI ROCKVILLE MD 20852 USA
- ZIP Code
- 20852
- Solicitation Number
- 75N91020R00008
- Response Due
- 1/27/2020 9:00:00 AM
- Archive Date
- 02/11/2020
- Point of Contact
- David Romley, Phone: 2402767822
- E-Mail Address
-
David.Romley@nih.gov
(David.Romley@nih.gov)
- Description
- SOURCES SOUGHT NOTICE: Breast Cancer Survivors Cohort � Late Effects of Breast Cancer Treatments Notice Number: 75N91020R00008 Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov� or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: January 27, 2020 by 12:00 pm Eastern This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified Small Business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned businesses that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 541690 with a size standard of 1,000 employees. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME.� However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI�s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. Background The Breast Cancer Survivors� Cohort Study is a large-scale retrospective cohort study of breast cancer survivors with the National Cancer Institute (NCI) to address questions about the late-effects of modern breast cancer treatments using with detailed treatment information. To address these issues, NCI previously contracted to obtain additional data to expand a cohort at Kaiser Permanente Washington (KPWA) of women diagnosed with stage I-II breast cancer between 1990-2008. The cohort expansion included extending stages to include 0 and III and expanded the years of diagnosis and follow-up from 1990-2016 (followed through 2017). The expansion involves using electronic medical records and radiotherapy records to study the late effects of radiotherapy, chemotherapy and hormonal treatment on risk of second cancers, cardiovascular disease and other late effects, while accounting for confounding by lifestyle factors such as obesity, hormonal (estrogen) use, and smoking use.� The study goals include ascertaining detailed radiotherapy records from which NCI will employ state-of-the-art dose reconstruction to evaluate the relationship between radiation dose to various organs and outcomes such as second cancer risks and cardiovascular outcomes. Objective The information obtained under the procurement will be used to evaluate the effects of breast cancer treatments including hormonal therapies, radiotherapy and chemotherapy on outcomes which include contralateral breast cancer (CBC), other second cancers, cardiovascular disease and death. The objectives of the procurement are: To retrieve radiation summaries and treatment plans for an estimated 2020 women in the KP-WA cohort (treated with radiotherapy, diagnosis years 1990-2016, stage I, II and III, for whom radiation summaries have not previously been obtained (list provided by NCI). To retrieve from KP-WA electronic files data on cardiovascular outcomes and risk factors, smoking-related conditions and height/weight data. Scope Specifically, the procurement includes: Radiotherapy study: The procurement will require KP-WA to retrieve and scan radiotherapy summaries from the medical charts for up to 2020 KP-WA breast cancer patients treated with radiotherapy who were diagnosed with stage I, II or III breast cancer diagnosed during 1990-2016, for whom radiation summaries have not previously been obtained (list to be provided by NCI). Cardiovascular study:� The procurement will require KP-WA to ascertain prevalence and incidence of cardiovascular disease (CVD), and other cardiac outcomes, and cardiac risk factors, as defined by NCI, for the entire cohort of women with invasive breast cancer (stages I, II, III) who were diagnosed 1990-2016 with follow-up through 2017. Smoking-related data and height/weight data: The procurement will require KP-WA to ascertain smoking-related data, as defined by NCI, and height/weight data from electronic medical files for the entire cohort of women with invasive breast cancer (stages I, II, III) who were diagnosed 1990-2016 with follow-up through 2017. The period of performance for this contract includes a base plus one option years. Base Period:� March 1, 2020 to February 28, 2021 Option Period 1: March 1, 2021 to February 28, 2022 How to Submit a Response: Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12-point font minimum) that clearly details the ability to perform the requirements of the notice described above.� All proprietary information should be marked as such.�� Responses should include a minimum of a one page resume of the individuals meeting the requirements, and up to two pages demonstrating experience over the past two years meeting the requirements of this notice.� Statements should also include an indication of current small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern�s name and address).� Responses will be reviewed only by NIH personnel and will be held in a confidential manner. Organizations shall demonstrate 1.) Technical Approach 2.) Personnel Requirements and Organizational Experience. � Due Date:� Capability statements are due no later than January 27, 2020 by 12:00 pm Eastern Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein.� All questions must be in writing and emailed to David.Romley@nih.gov.� A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government.� Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.� In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov.� No collect calls will be accepted.����Please reference number 75N91020R00008 on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a RFQ may be published in Fed Biz Opps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: David Romley at David.Romley@nih.gov. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/52c577341a6543909c3045b1c96cf4d8/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN05536112-F 20200117/200115230200 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |